Relay Therapeutics Inc - Asset Resilience Ratio
Relay Therapeutics Inc (RLAY) has an Asset Resilience Ratio of 62.53% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Relay Therapeutics Inc's Asset Resilience Ratio has changed over time. Check RLAY PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Relay Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RLAY market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $437.48 Million | 62.53% |
| Total Liquid Assets | $437.48 Million | 62.53% |
Asset Resilience Insights
- Very High Liquidity: Relay Therapeutics Inc maintains exceptional liquid asset reserves at 62.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Relay Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Relay Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Relay Therapeutics Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Relay Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 75.72% | $470.50 Million | $621.33 Million | +0.32pp |
| 2024-12-31 | 75.41% | $657.04 Million | $871.30 Million | +3.56pp |
| 2023-12-31 | 71.84% | $606.35 Million | $843.98 Million | -5.18pp |
| 2022-12-31 | 77.03% | $847.12 Million | $1.10 Billion | +9.80pp |
| 2021-12-31 | 67.23% | $677.95 Million | $1.01 Billion | +38.42pp |
| 2020-12-31 | 28.81% | $230.41 Million | $799.83 Million | -51.04pp |
| 2019-12-31 | 79.85% | $313.86 Million | $393.07 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $428.61 Million | -- |
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clin… Read more